Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Sparingly water-soluble drugs such as candesartan cilexetil offer challenges in developing a drug product with adequate bioavailability. The objective of the present study was to develop a tablet dosage form of candesartan cilexetil incorporating drug nanoparticles to increase its saturation solubility and dissolution rate for enhancing bioavailability while reducing variability in systemic exposure. The bioavailability of candesartan cilexetil is dissolution limited following oral administration. To enhance bioavailability and overcome variability in systemic exposure, a nanoparticle formulation of candesartan cilexetil was developed. Candesartan cilexetil nanoparticles were prepared using a wet bead milling technique. The milled nanosuspension was converted into solid intermediate using a spray drying process. The nanosuspensions were characterized for particle size before and after spray drying. The spray dried nanoparticles were blended with excipients for tableting. The saturation solubility and dissolution characteristics of the nanoparticle formulation were investigated and compared with commercial candesartan cilexetil formulation. The drug nanoparticles were evaluated for solid-state transitions before and after milling. This study demonstrated that tablet formulation incorporating drug nanoparticles showed significantly faster rate of drug dissolution in a discriminating dissolution medium as compared to commercially available tablet formulation. Systemic exposure studies in rats indicated a significant increase in the rate and extent of drug absorption.
Nekkanti
Vijaykumar
V
NCE and CPS Product Development, Dr Reddy's Laboratories Limited, Hyderabad, India.
Pillai
Raviraj
R
Venkateshwarlu
Vobalaboina
V
Harisudhan
T
T
D000284:Administration, Oral; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000818:Animals; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001713:Biphenyl Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004304:Dosage Forms; D004339:Drug Compounding / Q000295:instrumentation / Q000379:methods; D004867:Equipment Design; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D013777:Tetrazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D004304:Dosage Forms; D013777:Tetrazoles; C077793:candesartan cilexetil